MERZ NORTH AMERICA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1908-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.merzusa.com
Clinical Trials
50
Active:0
Completed:43
Trial Phases
5 Phases
Phase 1:1
Phase 2:1
Phase 3:11
+2 more phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (47 trials with phase data)• Click on a phase to view related trials
Not Applicable
27 (57.4%)Phase 3
11 (23.4%)Phase 4
7 (14.9%)Phase 1
1 (2.1%)Phase 2
1 (2.1%)A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Not Applicable
Recruiting
- Conditions
- Neuromuscular AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsAcetylcholine Release InhibitorsMembrane Transport ModulatorsMolecular Mechanisms of Pharmacological ActionCholinergic AgentsNeurotransmitter AgentsincobotulinumtoxinABotulinum Toxins, Type A
- Interventions
- Drug: NT 201 Placebo
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT07122193
- Locations
- 🇺🇸
Merz Investigative Site, Nashville, Tennessee, United States
A Study to Determine if RADIESSE® Dilute Treatment in Décolleté of Adult Women Affects Radiographic Imaging Assessments
Not Applicable
Recruiting
- Conditions
- Décolleté Wrinkles
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT07086248
- Locations
- 🇺🇸
Merz Investigative Site, Alpharetta, Georgia, United States
Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products
Not Applicable
Completed
- Conditions
- Injection Site Reaction
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06093815
- Locations
- 🇪🇸
Ocean Clinic - Av. Ramon y Cajal 7, 29601, Marbella, Spain
A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05784363
- Locations
- 🇺🇸
Merz Investigation Site #0010473, Los Angeles, California, United States
🇺🇸Merz Investigation Site #0010101, Coral Gables, Florida, United States
🇺🇸Merz Investigation Site #001097, Nashville, Tennessee, United States
Longitudinal Evaluation and Real-world Evidence of NT201
Terminated
- Conditions
- Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05222607
- Locations
- 🇺🇸
SkinDC, Arlington, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found